2021年呼吸危重症临床进展回顾
In this review, we outlined the clinical studies in critical care field of pulmonary medicine from November 1, 2020 to September 30, 2021.…
要点
- 高炎性表型重症COVID-19患者糖皮质激素治疗与28天死亡率降低相关。
- HFNC较常规氧疗改善AECOPD合并代偿性高碳酸血症呼吸衰竭患者预后。
- COVID-19急性呼吸衰竭HFNC治疗时清醒俯卧位减少治疗失败与插管需求。
核心结论
- 综述汇总的2021年度呼吸危重症临床研究为动态评估基础上的个体化呼吸支持提供了证据。
主要发现
- 中国COVID-19重症患者回顾性研究显示糖皮质激素治疗与高炎性表型患者28天死亡率降低相关。
- 住院COVID-19患者中地塞米松使随机化时接受有创机械通气或单纯吸氧者28天死亡率更低。
- 右美托咪定早期镇静在老年患者中显示降低90天死亡率的较高概率,与手术或非手术集群状态无关。
- HFNC较常规氧疗改善AECOPD合并急性代偿性高碳酸血症呼吸衰竭患者预后。
- COVID-19急性呼吸衰竭HFNC治疗时清醒俯卧位降低治疗失败发生率和插管需求。
关键数值与推荐
- 与压力-容积曲线指导PEEP滴定相比,电阻抗断层成像(EIT)指导PEEP滴定可能与驱动压和生存率改善相关。
- ECMO是重度ARDS患者的挽救性治疗,COVID-19患者ECMO辅助生存与中心既往一年ECMO经验及早期ECMO管理强相关。
- 与常规肺保护性机械通气相比,神经调节辅助通气(NAVA)缩短机械通气时间。
临床怎么用
- 对高炎性表型重症COVID-19患者可考虑糖皮质激素治疗。
- AECOPD合并代偿性高碳酸血症呼吸衰竭可优先选用HFNC。
- COVID-19急性呼吸衰竭HFNC治疗时可行清醒俯卧位以减少插管。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this review, we outlined the clinical studies in critical care field of pulmonary medicine from November 1, 2020 to September 30, 2021. A Chinese retrospective study for critically ill patients with COVID-19 showed that corticosteroid therapy was associated with a reduced 28-day mortality in patients with the hyperinflammatory phenotype. In hospitalized patients with COVID-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization, and early sedation with dexmedetomidine exhibited a high probability of reduced 90-day mortality in older patients regardless of operative or non-operative cluster status. High-flow nasal cannula (HFNC) improved the prognosis compared with conventional oxygen therapy in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients with acute compensated hypercapnic respiratory failure. For COVID-19 patients suffering from acute respiratory failure with HFNC therapy, awake prone positioning reduces the incidence of treatment failure and the need for intubation. Compared with pressure-volume curve guiding positive end-expiratory pressure (PEEP) titration for acute respiratory distress syndrome (ARDS) patients, PEEP titration guided with EIT (Electrical impedance tomography) might be associated with improved driving pressure and survival rate. Extracorporeal membrane oxygenation (ECMO) is a life-saving therapy for severe ARDS patients, but the survival among ECMO-assisted patients with COVID-19 is strongly associated with a centre's experience in ECMO during the previous year and early ECMO management. Compared to conventional lung-protective mechanical ventilation (MV), neurally adjusted ventilatory assist (NAVA) decreased duration of MV. These findings also provide evidence for improving the clinical management in critical care of pulmonary medicine. 呼吸危重症领域在2021年度(2020年10月1日到2021年9月30日)有了一些临床进展,重症肺炎发病早期、高炎性反应和病情较重的患者应用糖皮质激素有效;右美托咪定对年龄>65岁和外科术后有创机械通气患者能够获益;在呼吸支持领域,经鼻高流量湿化氧疗用于慢性阻塞性肺疾病急性发作、经鼻高流量湿化氧疗联合清醒俯卧位通气、有创机械通气患者采用电阻抗交点法指导滴定呼气末正压、早期应用体外膜氧合、结合神经调节辅助通气指导尽快撤机等相关研究,说明在动态评估的基础上采取个体化呼吸支持的重要性,这些研究成果相信也会对呼吸危重症患者临床救治提供证据支持。.
引用
- Song LC, Xie LX. [Clinical update in critical care of pulmonary medicine 2021]. Zhonghua Jie He He Hu Xi Za Zhi. 2022. PMID: 35000311. doi:10.3760/cma.j.cn112147-20211028-00745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。